Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Clinical High Risk Syndrome of Psychosis
Interventions
DIETARY_SUPPLEMENT

Sulforaphane

Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.

COMBINATION_PRODUCT

Placebo

The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.

Trial Locations (9)

200030

RECRUITING

Shanghai Mental Health Center, Shanghai

200032

NOT_YET_RECRUITING

Shanghai Xuhui District Mental Health Center, Shanghai

201300

RECRUITING

Suzhou Psychiatric Hospital, Suzhou

NOT_YET_RECRUITING

Shanghai Pudong Nanhui Mental Health Center, Shanghai

410008

RECRUITING

Second Xiangya Hospital of Central South University, Changsha

510009

NOT_YET_RECRUITING

Guangzhou Psychiatric Hospital, Guangzhou

518118

RECRUITING

Shenzhen Kangning Hospital, Shenzhen

Unknown

NOT_YET_RECRUITING

the First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Tianjin Anding Hospital, Tianjin

All Listed Sponsors
collaborator

Shanghai Xuhui District Mental Health Center

UNKNOWN

collaborator

Shanghai Pudong Nanhui Mental Health Center

UNKNOWN

collaborator

Suzhou Psychiatric Hospital

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

collaborator

Guangzhou Psychiatric Hospital

OTHER_GOV

collaborator

Shenzhen Fushan Biotech Co., Ltd.

UNKNOWN

collaborator

Tianjin Anding Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Shenzhen Kangning Hospital

OTHER

lead

Shanghai Jiao Tong University School of Medicine

OTHER